Vaccines and Related Biological Products Advisory Committee; Notice of Meeting, 36796-36797 [2017-16519]
Download as PDF
36796
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
user fee provisions of the FD&C Act, and
the procedures for submitting requests
for waivers or reductions. It also
includes recommendations for
submitting information for requests for
reconsideration of denials of waiver or
reduction requests, and for requests for
appeals. The guidance also provides
clarification on related issues such as
user fee exemptions for orphan drugs.
Based on Agency records, we estimate
that the total annual number of waiver
requests submitted for all of these
categories will be 150, submitted by 115
different applicants. We estimate that
the average burden hours for
preparation of a submission will total 16
hours. Because FDA may request
additional information from the
applicant during the review period, we
have also included in this estimate time
to prepare any additional information.
We have included in the burden
estimate the preparation and submission
of application fee waivers for small
businesses, because small businesses
requesting a waiver must submit
documentation to FDA on the number of
their employees and must include the
information that the application is the
first human drug application, within the
meaning of the FD&C Act, to be
submitted to the Agency for approval.
Previously, after receipt of a small
business waiver request, FDA would
request a small business size
determination from the Small Business
Administration (SBA). Waiver
applicants would submit their
supporting documentation directly to
SBA for evaluation and after completing
their review, SBA provided FDA with a
determination whether a waiver
applicant qualified as a small business
for purposes of evaluating user fee
waivers. The burden for submission of
this information to SBA is approved
under OMB control number 3245–0101.
Beginning fiscal year 2015, the SBA
declined to conduct further size
determinations for evaluation of small
business user fee waivers and as a
result, a processing change at FDA
occurred. The new FDA process
requires waiver applicants to submit
documentation directly to FDA. In
addition, fewer supporting documents
than previously requested by SBA are
required. As a result, we estimate that
the 4 burden hours per small business
waiver previously attributed to SBA and
approved under OMB control number
3245–0101, should now be attributed to
FDA because SBA is no longer
conducting size determinations for FDA.
Also, because FDA is asking that
applicants submit fewer supporting
documents, we estimate that these
burden hours should be reduced to 2
hours instead of 4 hours. We understand
that SBA plans to submit a revised
burden estimate to OMB control number
3245–0101 to account for this
redistribution.
The reconsideration and appeal
requests are not addressed in the FD&C
Act, but are discussed in the guidance.
We estimate that we will receive seven
requests for reconsideration annually,
and that the total average burden hours
for a reconsideration request will be 24
hours. In addition, we estimate that we
will receive one request annually for an
appeal of a user fee waiver
determination, and that the time needed
to prepare an appeal would be
approximately 12 hours. We have
included in this estimate both the time
needed to prepare the request for appeal
to the Chief Scientist, User Fee Appeals
Officer, Office of the Commissioner, and
the time needed to create and send a
copy of the request for an appeal to the
Director, Division of User Fee
Management, Office of Management,
Center for Drug Evaluation and
Research.
The burden for completing and
submitting Form FDA 3397
(Prescription Drug User Fee Coversheet)
is not included in this analysis as the
burden is included under OMB control
number 0910–0297. The collections of
information associated with submission
of a new drug application or biologics
license application are approved under
OMB control numbers 0910–0001 and
0910–0338, respectively.
In the Federal Register of May 23,
2017 (82 FR 23581), FDA published a
60-day notice requesting public
comment on the proposed extension of
this collection of information. No
comments were received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
User fee waivers, reductions, & refunds for
drug & biological products
Number of
responses per
respondent
Number of
respondents
Total annual
responses
Average
burden per
response
Total hours
FD&C Act sections 735 and 736 .......................................
FD&C Act section 736(d)(1)(D)(4) .....................................
Reconsideration requests ..................................................
Appeal requests .................................................................
115
25
7
1
1.3
1
1
1
150
25
7
1
16
2
24
12
2,400
50
168
12
Total ...................................................................................
........................
..........................
........................
........................
2,630
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: August 2, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[FR Doc. 2017–16580 Filed 8–4–17; 8:45 am]
[Docket No. FDA–2017–N–0001]
mstockstill on DSK30JT082PROD with NOTICES
BILLING CODE 4164–01–P
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
The meeting will be held on
September 13, 2017, from 8:30 a.m. to
5 p.m.
DATES:
HHS.
ACTION:
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
PO 00000
The Food and Drug
Administration (FDA or the Agency)
announces a forthcoming public
advisory committee meeting of the
Vaccines and Related Biological
Products Advisory Committee
(VRBPAC). The general function of the
committee is to provide advice and
recommendations to the Agency on
FDA’s regulatory issues. The meeting
will be open to the public.
SUMMARY:
Notice.
Frm 00069
Fmt 4703
Sfmt 4703
E:\FR\FM\07AUN1.SGM
07AUN1
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503), Silver Spring, MD 20993–0002.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
Serina Hunter-Thomas or Rosanna
Harvey, Center for Biologics Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 6307C, Silver
Spring, MD 20993–0002; 240–402–5771,
serina.hunter-thomas@fda.hhs.gov and
240–402–8072, rosanna.harvey@
fda.hhs.gov; or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On September 13, 2017, the
VRBPAC will meet in an open session
to discuss and make recommendations
on the safety and effectiveness of Zoster
Vaccine Recombinant, Adjuvanted,
manufactured by GlaxoSmithKline
Biologicals. FDA intends to make
background material available to the
public no later than 2 business days
before the meeting. If FDA is unable to
post the background material on its Web
site prior to the meeting, the background
material will be made publicly available
at the location of the advisory
committee meeting, and the background
material will be posted on FDA’s Web
site after the meeting. Background
material is available at https://
www.fda.gov/AdvisoryCommittees/
Calendar/default.htm. Scroll down to
the appropriate advisory committee
meeting link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before September 6, 2017.
Oral presentations from the public will
mstockstill on DSK30JT082PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
be scheduled between approximately
1:30 p.m. and 2:30 p.m. Those
individuals interested in making formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before August 29, 2017. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 30, 2017.
Web cast: For those unable to attend
in person, the meeting will also be web
cast and will be available at the
following link: https://
collaboration.fda.gov/vrbpac0917/.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Serina HunterThomas at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at:
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 1, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–16519 Filed 8–4–17; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
36797
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0085]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Guidance for
Industry: Cooperative Manufacturing
Arrangements for Licensed Biologics
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the proposed
extension of the collection of
information concerning cooperative
manufacturing arrangements for
licensed biologics.
DATES: Submit either electronic or
written comments on the collection of
information by October 6, 2017.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before October 6,
2017. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of October 6, 2017. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
E:\FR\FM\07AUN1.SGM
07AUN1
Agencies
[Federal Register Volume 82, Number 150 (Monday, August 7, 2017)]
[Notices]
[Pages 36796-36797]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16519]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) announces
a forthcoming public advisory committee meeting of the Vaccines and
Related Biological Products Advisory Committee (VRBPAC). The general
function of the committee is to provide advice and recommendations to
the Agency on FDA's regulatory issues. The meeting will be open to the
public.
DATES: The meeting will be held on September 13, 2017, from 8:30 a.m.
to 5 p.m.
[[Page 36797]]
ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-
0002. Answers to commonly asked questions including information
regarding special accommodations due to a disability, visitor parking,
and transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT: Serina Hunter-Thomas or Rosanna
Harvey, Center for Biologics Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6307C, Silver
Spring, MD 20993-0002; 240-402-5771, serina.hunter-thomas@fda.hhs.gov
and 240-402-8072, rosanna.harvey@fda.hhs.gov; or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area). A notice in the Federal Register about last minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On September 13, 2017, the VRBPAC will meet in an open
session to discuss and make recommendations on the safety and
effectiveness of Zoster Vaccine Recombinant, Adjuvanted, manufactured
by GlaxoSmithKline Biologicals. FDA intends to make background material
available to the public no later than 2 business days before the
meeting. If FDA is unable to post the background material on its Web
site prior to the meeting, the background material will be made
publicly available at the location of the advisory committee meeting,
and the background material will be posted on FDA's Web site after the
meeting. Background material is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate
advisory committee meeting link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
September 6, 2017. Oral presentations from the public will be scheduled
between approximately 1:30 p.m. and 2:30 p.m. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before August 29, 2017. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by August 30, 2017.
Web cast: For those unable to attend in person, the meeting will
also be web cast and will be available at the following link: https://collaboration.fda.gov/vrbpac0917/.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Serina Hunter-Thomas at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: August 1, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-16519 Filed 8-4-17; 8:45 am]
BILLING CODE 4164-01-P